Table 1

Overview of included QOF (2004/2005) indicators and economic evidence.

IndicatorDescriptionMaximum points available for indicatorMean annual payment received per treated patient, £Mean utilisation level for indicator in 2004/2005, %Evidence ratinga and sourceIncremental cost per QALY gained, £
BP5The percentage of patients with hypertension in whom the last blood pressure (measured in last 9 months) is 150/90 mmHg or less568.3571.3Indicative15989
CHD9The percentage of patients with CHD with a record in the last 15 months that aspirin, an alternative antiplatelet therapy, or an anticoagulant is being taken (unless a contraindication or side-effects are recorded)72.6490.0Robust16Dominant (less costly and more effective than comparator)b
CHD10The percentage of patients with CHD who are currently treated with a beta-blocker (unless a contraindication or side-effects are recorded)74.7763.2Indicative1758
CHD11The percentage of patients with a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an ACE inhibitor740.6185.6Robust185623
CS1The percentage of patients aged 25–64 years (in Scotland 25–60 years) whose notes record that a cervical smear has been performed in the last 3 to 5 years110.6380.2Indicative19458
DM15The percentage of patients with diabetes with proteinuria or micro-albuminuria who are treated with ACE inhibitors (or A2 antagonists)317.8682.1Indicative20Dominantb
DM21The percentage of patients with diabetes who have a record of retinal screening in the previous 15 months51.9783.2Robust2115 654
LVD3The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or or A2 antagonist, who can tolerate therapy and for whom there is no contraindication1036.2582.1Indicative22109
Stroke12The percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record that an antiplatelet agent (aspirin, clopidogrel, dipyridamole or a combination), or an anticoagulant is being taken (unless a contraindication or side-effects are recorded)46.0089.3Robust162012
  • A2 antagonist = Angiotensin II antagonists. ACE = angiotensin-converting enzyme. CHD = coronary heart disease. LVD = left ventricular dysfunction. TIA = transient ischaemic attack.

  • a Evidence rating based on how closely they met the following criteria: UK based, relevant treatment and comparator, quality adjusted life years (QALYs) as measure of outcome and recently published.

  • b While these treatments may be assumed to increase cost in the short term, they decrease healthcare costs in the long run, resulting in cost savings; for example, through reduced hospitalisations.